Drug Safety

, Volume 29, Issue 10, pp 999–999 | Cite as

ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

  • J. J. Gagnier
  • H. Boon
  • P. Rochon
  • D. Moher
  • J. Barnes
  • C. Bombardier
Abstracts

Keywords

Canadian Institute Consensus Meeting Item Generation Consort Statement Clinical Trial Reporting 

References

  1. 1.
    Schulte-Lobbert S, Holloubek G, Muller WE, et al. Comparison of the synapotosomal uptake inhibition of serotonin by St. John’s wort products. J Pharm Pharmacol 2004; 56(6): 813–8PubMedCrossRefGoogle Scholar
  2. 2.
    Kressmann S, Biber A, Wonnemann M, et al. Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations. J Pharm Pharmacol 2002; 54(11): 1507–14PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • J. J. Gagnier
    • 1
  • H. Boon
    • 2
  • P. Rochon
    • 3
  • D. Moher
    • 4
  • J. Barnes
    • 5
  • C. Bombardier
    • 6
  1. 1.Windsor, Canada; Faculty of PharmacyUniversity of TorontoTorontoCanada
  2. 2.Baycrest Centre for Geriatric CareTorontoCanada
  3. 3.Children’s Hospital of Eastern Ontario Research InstituteOttawaCanada
  4. 4.School of Pharmacy, Faculty of Medical and Health SciencesOttawaCanada
  5. 5.University of AucklandAucklandNew Zealand
  6. 6.Institute for Work and HealthTorontoCanada

Personalised recommendations